Perioperative chemotherapy in locally advanced gastric cancer. A retrospective study about 25 cases

##plugins.themes.academic_pro.article.sidebar##

Published Aug 21, 2015
Download
pdf
Vol. 93 No. 4 (2015): Issue Apr 2015

##plugins.themes.academic_pro.article.main##

Ben Nasr Sonia
Ayadi Mouna
Bahloul Rim
Guesmi Sondes
Allani Bassem
Chrait Nesrine
Rifi Héla
Rais Henda
Mezlini Amel

Abstract

Background: Perioperative chemotherapy containing 5FU, Cisplatin ± Docetaxel is one of the most active regimens in advanced gastric cancer.
Objective: To report epidemiological and clinical profile and therapeutic results of perioperative chemotherapy in locally advanced gastric cancer in Tunisia.
Methods: Our retrospective study concerned patients with histologically confirmed advanced gastric cancer treated at the institute Salah Azaiez of Tunis. They received 2-3 cycles / 3 weeks of neoadjuvant chemotherapy based on FP (5FU and Cisplatin) or TPF (Docetaxel-Cisplatin-5FU).
Results: From 2010 to 2012, 25 patients with a median age of 60 years and 7.3 sex-ratio received neoadjuvant chemotherapy. Protocols used were TFP in 20 and FP in 5 patients, 17 patients receiving more than 2 cycles. Side effects were represented by mucositis grade 3 in 2 patients, neutropenia grade ¾ in 3 patients and renal failure in 5 patients. After neoadjuvant chemotherapy, we observed 40% of partial response and 20% of stable disease. Six patients (24%) underwent surgery, curative in 4 (R0 in 3 cases) by total gastrectomy and D2 lymphadenectomy and palliative in 2 cases due to peritoneal carcinomatosis. With a median follow up of 16 months, median overall survival was 16 months (2-21 months).
Conclusion: Probably due to the very bulky and advanced stages of our gastric cancer cases, neoadjuvant chemotherapy using FP±T showed no benefit in the treatment of locally advanced gastric cancer in Tunisian patients.

Keywords:

Gastric cancer, neoadjuvant chemotherapy, surgery, response.

##plugins.themes.academic_pro.article.details##

References

  1. Bouchbika Z, Quero L, Kouto H et al. Adjuvant chemotherapy followed by conformal chemoradiotherapy in gastric carcinoma. Cancer Radiother 2008; 12: 775-80.
  2. Ychou M, Gory-Delabaere G, Blanc P et al. Recommendations for clinical practice: Standards, Options and Recommendations 2004 for radiotherapeutic treatment of gastric adenocarcinoma (cardial cancers, other histological types excluded). Standards, Options and Recommendations. Cancer Radiother 2004; 8: 322-35
  3. Cunningham D, Allum WH, Stenning SP et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med 2006; 355:11-20.
  4. Bain GH, Petty RD. Predicting Response to Treatment in Gastroesophageal Junction Adenocarcinomas: Combining Clinical, Imaging, and Molecular Biomarkers. The Oncologist 2010;15:270-284.
  5. Ottini L, Falchetti M, Lupi R et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006; 17 (7): 97-102.
  6. Rivera F, Vega-Villegas ME, López-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007;33(4):315-24.
  7. Michel P. Gastric cancer. Treatment in 2008. Cancer Radiother 2008; 12: 649-652.
  8. Michel P. Clinical case: perioperative chemotherapy of gastric cancer: for whom? which risks? Gastroenterol Clin Biol 2009; 33: 280-4
  9. Boige V, Pignon JP, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007; 25: 4510.
  10. Van Cutsem E, Moiseyenko VM, Tjulandin S. Docetaxel - Cisplatin - 5- fluorouracil versus cisplatin - 5-fluorouracil in first-line metastatic or recurrent gastric cancer. A. J Clin Oncol 2006;24:4991-7.
  11. Höfler H, R Langer R, Ott K et al. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Recent Results Cancer Res 2007;176:33-6.